Amgen, USB Pharma and Astellas funded the study, and Dr. McClung and other study authors report financial relationships with Amgen and other drug companies.
You Might Also Like
Also By This Author
ad goes here:advert-1
SCROLL TO CONTINUE
- McClung MR, Brown JP, Diez-Perez A, et al. Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: A randomized, double-blind, phase 2, parallel group study. Journal of Bone Mineral Research. 2018 Apr 25. [Epub ahead of print]